Log in
Email Address
Password
Forgot your password?
Not Registered?

Featured Tenants

 cfai

The Centre for Advanced Instrumentation at the NETPark Research Institute collaborates with observatories world-wide in the construction, commissioning and exploitation of innovative hi-tech instruments for optical and infrared astronomy. Key research areas are advanced spectroscopy, adaptive optics, applied optics, low light level detectors and precision engineering/metrology.

Click here to learn more about Centre for Advanced Instrumentation

Featured Opportunity
An Improved Microgripper for Cell Manipulation

There is a growing need for individual cell manipulation in a wide range of research applications including stem cell sorting, gene and molecular delivery, cellular diagnostics, and single cell-based assays. When compared with data-averaging over a cell population, direct physical cell manipulation offers the researcher much more precise selection and understanding of cell properties.


For further information click here

Polls



CDEP logo

cddc   European Union emblem

Company announces MRSA detector
Bookmark and Share Add This     Email notification Email a Friend    print Printable version

Company announces MRSA detector

2008-04-23
Newsfeed

The Finnish biotechnology company Mobidiag has announced the Prove-it(TM) Bacteria test that sets a world record by being able to detect 50 dangerous bacteria simultaneously - including the widespread "superbug" MRSA.

The Finnish biotechnology company Mobidiag has announced the Prove-it(TM) Bacteria test that sets a world record by being able to detect 50 dangerous bacteria simultaneously - including the widespread "superbug" MRSA.

This is an important milestone in the battle against infectious diseases, most importantly life-threatening sepsis.

Sepsis is a growing cause of death worldwide - there are around 3 million sepsis cases annually, over 500,000 of them resulting in death. Sepsis is an infection caused by a number of micro-organisms spreading in the bloodstream. The challenge in sepsis treatment is starting adequate treatment with the appropriate antibiotics on time.

"The test helps clinicians make better and faster decisions and provide sufficient treatment for seriously ill patients. This offers huge savings, as sepsis treatment currently consumes billions of euros annually. Our target is to have a single test that reliably detects the majority of dangerous human disease causing bacteria and Prove-it(TM) Bacteria test is an important milestone on that road," says Jaakko Pellosniemi, CEO of Mobidiag.

Prove-it(TM) Bacteria test is intended for research purposes. The evaluation aiming for the European CE-IVD status enabling its use in clinical sepsis diagnostics is currently ongoing and will be completed later this year. The test will cover more than 90 % of all sepsis cases.

Copyright © The Press Association 2008


Add Comment | View All Comments (0)


Related Links